SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) was featured in a BioMedWire editorial examining the rapid growth of the GLP-1 market, highlighting the company’s subsidiary GlucaPharm Inc. and its development of GEP-44, a patented triple agonist peptide licensed from Syracuse University. The editorial notes that GEP-44 is designed to target GLP-1 and peptide YY receptors Y1 and Y2, positioning SureNano as an emerging microcap participant seeking to address limitations of first-generation GLP-1 therapies, including efficacy, tolerability and delivery flexibility.
The coverage places SureNano alongside established and emerging metabolic disease companies including Merck & Co. (NYSE: MRK), AbbVie (NYSE: ABBV), Viking Therapeutics (NASDAQ: VKTX) and Altimmune (NASDAQ: ALT), underscoring accelerating momentum across the obesity, diabetes and cardiometabolic treatment landscape. BioMedWire notes SureNano’s broader platform strategy, including evaluation of oral, sublingual and intranasal delivery approaches, as well as early-stage opportunities involving formulation and delivery technologies that could expand the company’s long-term therapeutic scope.
SureNano Science Ltd. is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical and biotechnology assets with the potential to address large and growing global health markets. The company has acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company developing GEP44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential non-injectable delivery (refer to press release dated February 23, 2026). The initial business of SureNano Science Ltd. is the sale and distribution of the SureNano(TM) surfactant, which is a ready-to-mix food grade compound that provides the base for high performance nanoemulsions to create incredibly homogeneous and stable products while maximizing bioavailability, clarity, and taste. The Company has an exclusive license to distribute the SureNano(TM) surfactant within Canada; Oklahoma, USA; and Colorado, USA. SureNano Science Ltd. is now developing into a pharmaceutical focused company through the advancement of a patented therapeutic candidate designed to address obesity and metabolic disease.
The editorial highlights that the GLP-1 market is experiencing rapid growth, with first-generation therapies facing limitations that next-generation agents like GEP-44 aim to overcome. For leaders in business and technology, this development signals a shift toward more effective and patient-friendly treatments for obesity and diabetes, potentially reshaping the competitive landscape and opening new opportunities in drug delivery systems. The evaluation of oral, sublingual, and intranasal delivery methods could reduce reliance on injections, improving patient compliance and expanding market access.
For investors, SureNano’s positioning as an emerging microcap in the metabolic disease space, alongside larger players such as Merck and AbbVie, suggests potential for significant upside if GEP-44 succeeds in clinical development. The company’s broader platform strategy, including formulation and delivery technologies, offers additional avenues for growth beyond the initial peptide candidate.
To view the full press release, visit https://ibn.fm/2NGrw. For the latest news and updates relating to SURNF, visit the company’s newsroom at https://ibn.fm/SURNF.
